<DOC>
	<DOCNO>NCT01456767</DOCNO>
	<brief_summary>The design study conforms randomize double-blind placebo-controlled cross-over design . The objective study ass effect three probiotic ( Lactobacillus plantarum WCFS1 , Lactobacillus plantarum CIP104448 , Lactobacillus plantarum CIP104450 ) intestinal epithelial permeability immune system , least 8 healthy subject . The effect three different probiotic placebo assess every subject random sequence . Prior start 7-days supplementation period ( one three probiotic supplement placebo ) , blood sample obtain small intestinal permeability assess measure urinary extraction ratio ingest water-soluble , non-degradable test probe , without indomethacin challenge ( compromise gut ) . After supplementation period gut stress indomethacin protocol , follow measurement small intestinal permeability , whereupon blood sample take duodenal tissue sample obtain standard gastroduodenoscopy . Each supplementation period start 1 month finish pervious test episode , randomize sequence . The primary objective study assess effect Lactobacillus plantarum WCFS1 , Lactobacillus plantarum CIP104448 , Lactobacillus plantarum CIP104450 intestinal epithelial permeability . Secondary objective assess effect immune modulation , gene expression peripheral blood mononuclear cell , small intestine epithelial gene regulation tight junction protein modulation , infiltration immune cell intestinal mucosa immune marker blood plasma . The investigator hypothesize Lactobacillus plantarum WCFS1 , Lactobacillus plantarum CIP104448 , Lactobacillus plantarum CIP104450 , separately , significantly affect innate immune system intestinal permeability human .</brief_summary>
	<brief_title>Effects Administration L.Plantarum WCFS1 , L.Plantarum CIP104448 , L.Plantarum CIP104450 Small Intestinal Mucosa</brief_title>
	<detailed_description />
	<criteria>Based medical history previous selfadmitted examination , gastrointestinal complaint define . Age 18 65 year . BMI 20 30 kg/m2 . History severe cardiovascular , respiratory , urogenital , gastrointestinal/ hepatic , hematological/immunologic , HEENT ( head , ears , eye , nose , throat ) , dermatological/connective tissue , musculoskeletal , metabolic/nutritional , endocrine , neurological disease , allergy , major surgery and/or laboratory assessment might limit participation completion study protocol . Use medication , include vitamin supplementation , except oral contraceptive , within 14 day prior test . Administration investigational drug participation scientific intervention study may interfere study ( decided principle investigator ) , 180 day prior study . Major abdominal surgery interfere gastrointestinal function ( uncomplicated appendectomy , cholecystectomy hysterectomy allow , surgery upon judgement principle investigator ) . Pregnancy , lactation . Excessive alcohol consumption ( &gt; 20 alcoholic consumption per week ) . Smoking . Blood donation within 3 month study period . Selfadmitted HIVpositive state . Known hypersensitivity history allergic reaction towards intake nonsteroidal antiinflammatory drug ( NSAIDs ) non low caloric sweetener kind . History side effect towards intake pro prebiotic supplement kind .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>